Clinical Trial Update: Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating camrelizumab plus apatinib and nab-paclitaxel for second-line advanced gastric cancer (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer

Drugs mentioned

• Apatinib Mesylate Tablets (Apatinib)
• Camrelizumab (camrelizumab)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Locally Advanced or Metastatic Gastric Adenocarcinoma | Phase 1, Phase 2 | Status: UNKNOWN